Kurt H Kruger
CIK 1375881 · Chief Financial Officer · last filed 2022-08-04
Kurt H Kruger is a Chief Financial Officer who has filed 10 SEC Form 4 insider transactions across 1 company since 2020. The most recent filing, for QLGN, was dated Aug 4, 2022. Across all open-market trades the lifetime net is +$42.4K, making them a net buyer over the disclosed history.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$0
1
10
$42.4K
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Qualigen Therapeutics, Inc. (QLGN) Delisted | Director | 18,000 | $3.21 | $57.8K | $42.4K | 6 | 2022-08-04 |
Recent Filings
10 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2022-08-04 | Qualigen Therapeutics, Inc. (QLGN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-08-20 | Qualigen Therapeutics, Inc. (QLGN) Delisted | Buy (P) | +8,000 | $9.8K | EDGAR |
| 2020-12-30 | Qualigen Therapeutics, Inc. (QLGN) Delisted | Buy (P) | +4,000 | $11.7K | EDGAR |
| 2020-11-23 | Qualigen Therapeutics, Inc. (QLGN) Delisted | Buy (P) | +6,000 | $20.9K | EDGAR |
| 2020-06-08 | Qualigen Therapeutics, Inc. (QLGN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2020-05-27 | Qualigen Therapeutics, Inc. (QLGN) Delisted | Other (J) | — | $0 | EDGAR |
| 2018-08-16 | — | Grant (A) | — | $0 | |
| 2007-11-16 | — | Grant (A) | +100,000 | $0 | |
| 2007-03-06 | — | Grant (A) | +8,297 | $9.4K | |
| 2007-03-01 | — | Grant (A) | — | $0 |